CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Intellipharmaceutics International Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Intellipharmaceutics International Inc
30 Worcester Rd
Phone: (416) 798-3001p:416 798-3001 ETOBICOKE, ON  M9W 5X2  Canada Fax: (403) 567-0339f:403 567-0339
Filed for Bankruptcy on 10/31/2024
On 10/31/2024, Intellipharmaceutics International Inc. filed an assignment in Bankruptcy
KPMG Inc. was appointed as the trustee-in-Bankruptcy of the Estates of the Bankrupt by the Official Receiver
This company is no longer actively traded on any major stock exchange.
Business Summary
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Company’s abuse-deterrent oxycodone hydrochloride extended-release formulation (Oxycodone ER) based on its proprietary nPODDDS novel Point of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). Its product portfolio includes both new products and controlled-release generic products.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
8/31/202311/30/2022YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer, Co-Chief Scientific Officer IsaOdidi 1/1/2020 10/19/2009
President, Acting Chief Financial Officer, Chief Operating Officer, Co-Chief Scientific Officer, Di AminaOdidi 1/1/2020
Vice President - Chemistry and Analytical Services Patrick N.Yat 1/1/2017 10/19/2009
3 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Intellipharmaceutics Corp 30 Worcester Rd Etobicoke ON Canada
Intellipharmaceutics Ltd. 30 Worcester Road Toronto ON Canada

Business Names
Business Name
Intellipharmaceutics Corp.
IPC Ltd.
Vasogen Corp.

General Information
Outstanding Shares: 33,092,665 (As of 8/31/2023)
Shareholders: 1,667
Stock Exchange: NEX
Fax Number: (403) 567-0339


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, January 29, 2025